Mechanisms of TGF-beta mediated tumour promotion in RDEB cSCCOngoing
|Project lead||Prof. Gareth Inman|
|Organisation||Cancer Research UK Beatson Institute, University of Glasgow, Scotland, UK|
|Partner organizations & collaborators||Dr Peter Bailey, Dr Karen Blyth (Glasgow, Scotland, UK) and Dr. Andrew South (Thomas Jefferson University, Philadelphia, US).|
|Project budget||GBP 78,613.00|
|Start date / Duration||02. Jan 2019 / 12 months|
|Funder(s) / Co-Funder(s)||DEBRA UK|
|Research area||Skin cancer & fibrosis|
Short lay summary
Recessive Dystrophic epidermolysis bullosa (RDEB) is an inherited disorder associated with chronic blistering, wounding and excessive scarring of the skin. A high proportion of RDEB patients develop a skin cancer called cutaneous squamous cell carcinoma (cSCC), which is often fatal. Cells within the body rely on specific signals for survival and growth. In cancer these signals are either lost or can be elevated to assist tumour growth and spread.
This research group and others have recently shown that a specific signalling system, involving a molecule called Transforming Growth Factor- beta (TGF-β), is elevated in the skin of people with RDEB related cSCC. Importantly this group has found that blocking active TGF-β signalling can inhibit (stop) cancer cell growth in 50% of RDEB samples tested. Interestingly, blocking the signaling pathway can also promote cancer cell growth in selected RDEB cSCC samples.
These observations indicate that it is critical to understand when and how TGF-β functions to promote or suppress cancer growth in RDEB to enable identification of patients that will benefit from inhibiting this signaling pathway. In this project the group plan to investigate how TGF-β promotes cancer growth and to achieve this, the group aims to develop biomarkers of TGFβ signalling using in-vitro and in-vivo state of the art biological assays, (procedures used to analyse the behaviour and activity of molecules).
This research will provide the basis for further understanding of TGFβ signaling in RDEB and could identify new targets for future drug development to treat squamous cancers. These therapies are in clinical trials in other cancers or are in pre-clinical development already. The study will also inform on avenues of novel therapeutic development.
To understand the molecular characteristics (biomarkers) of how TGFβ behaves in RDEB skin cancer that will inform the use of an anti - TGFβ signalling therapy.
Understand the mechanism of how TGFβ signalling can lead to cancer migration, invasion and tumour growth and identify targets for therapeutics (e.g. a protein or molecule that can be modified using a drug or treatment to target cancer cells).